reports
Crossject : Information relative au nombre total de droits de vote et ...
Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 10 avril 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et commercialisera prochainement un portefeuille de médicaments dédiés aux situations d’urgence, publie conformément aux articles 223-16 du Règlement général de l’AMF et L.233-8 II du Code de commerce, le nombre total de droits de vote et d’actions composant son capital social au 31...
- Olfa Taamallah
- Yan Derocles
ODDO BHF Small & MIDCAP MORNING NEWS - 03/04/2024
La solidité de l’économie américaine et l’amélioration du sentiment macroéconomique en Europe nous conduisent à maintenir nos calls gagnants : long USA vs Europe et - en Europe - long Cycliques vs Défensives. Toujours en Europe, nous basculons long Value vs Growth et modifions en profondeur notre allocation sectorielle ; nous y intégrons également une analyse chartiste. Nos secteurs préférés sont : Banks, Financial Services, Insurance, Media, Energy, Industrial Goods & Services, Tra...
- Olfa Taamallah
- Yan Derocles
ODDO BHF Small & MIDCAP MORNING NEWS - 04/03/2024
America’s solid economy and Europe’s improving macro sentiment have prompted us to reiterate our winning calls: long USA vs Europe and - within Europe - long Cyclicals vs Defensives. Also within Europe, we are switching to long Value vs Growth and have overhauled our sector allocation ; furthermore it nows incorporates a chart analysis. Our favourite sectors are as follows: Banks, Financial Services, Insurance, Media, Energy, Industrial Goods & Services, Travel & Leisure, Constructio...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Fabrice Farigoule
Patience is a virtue… hopefully
Patience is a virtue… hopefully EARNINGS/SALES RELEASES The group took the market by surprise, issuing a press release on the progress made in its US strategy and a (very summarized) set of results for FY23. We mostly see negative points in this release and the hope of Zeneo reaching the US market through an EUA in FY24 have vanished… we will downgrade our numbers after the release of the FY23 detailed results, in particular by postponing the launch of the group’s NTEs. FACT Crossject issued...
- Martial Descoutures
- Oussema Denguir
Crossject : Avancements réglementaires et besoin de financement au cœu...
>Besoin de financement à court terme - Crossject a publié hier ses chiffres au titre de l’exercice 2023. Les produits d’exploitation progressent de 32% à 12.8 M€ notamment grâce à l’augmentation des frais de R&D facturés à la BARDA (6.7 M€ contre 1.8 M€ en 2022). Les charges d’exploitation demeurent relativement stables à 25.1 M€ pour une perte opérationnelle de -12.3 M€.La trésorerie à fin 2023 s’élevait à 2.3 M€, celle-ci ne prend pas en compte la 1ère tranche...
- Martial Descoutures
- Oussema Denguir
Crossject : Focus on regulatory advances and funding requirements in t...
>Short-term financing requirement - Crossject reported its 2023 figures yesterday. Operating income rose by 32% to € 12.8m, thanks to an increase in R&D expense billed to BARDA (€ 6.7m vs € 1.8m in 2022), while operating expense was relatively flat at € 25.1m, for an operating loss of -€ 12.3m.Cash at end-2023 stood at € 2.3m, but this does not include the initial tranche of € 7m of financing obtained from Heights Capital. The group’s cash position will allow it...
Crossject trading on Euronext to resume as usual on Wednesday April 3
Crossject trading on Euronext to resume as usual on Wednesday April 3 Dijon, France April 2, 2024 – Trading of the stock of Crossject (ISIN: FR0011716265; Euronext: ALCJ) on the Euronext exchange will resume as normal on Wednesday, April 3 at 09:00 CET. Crossject’s press release, entitled “Crossject advances in its U.S. Strategy and reports Financial Results for 2023”, was published at 10:30am CET, due to a delay in receiving certain confirmations. For that reason, Crossject required Euronext to stop trading. Following Euronext’s standard procedure in such cases, trading will restart ...
Crossject advances in its U.S. Strategy and reports Financial Results ...
Crossject advances in its U.S. Strategy and reports Financial Results for 2023 Increase in visibility in its regulatory and commercialization prospects in the U.S. since latest interactions with the FDAExpectation to receive U.S. Emergency Use Authorization (EUA) for ZEPIZURE® in Q1 2025Expectation to complete U.S. New Drug Application (NDA) for ZEPIZURE® in H1 2025Reinforcement of supply chain [with addition of a second fill-and-finish CDMO]Reporting of a reduced Net loss of €8.5 million versus €11.2 million in 2022 Dijon, France April 2, 2024, 10:30am CET -- Crossject (ISIN: FR0011716265...
Crossject poursuit sa stratégie de développement aux États-Unis et pub...
Crossject poursuit sa stratégie de développement aux États-Unis et publie ses résultats financiers pour 2023 Amélioration notable de la visibilité sur les perspectives règlementaires et commerciales aux États-Unis depuis les derniers échanges avec la FDA. Attente d’une obtention de l’Autorisation d’Utilisation d’Urgence (EUA) aux États-Unis pour ZEPIZURE® pour T1 2025. Attente d’un dépôt de la demande d’autorisation de mise sur le marché (NDA) de ZEPIZURE® aux États-Unis pour S1 2025. Renforcement de la supply chain avec l’addition d’un second façonnier. Annonce d’une réduction de la pe...
Crossject gender equality score reaches 96/100 in 2024
Crossject gender equality score reaches 96/100 in 2024 Dijon, France, March 8, 2024 – 7:30 pm CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, today announces its EU Gender Equality Index score reached 96/100 for 2024, marking the third successive year it has been above 90%. The Gender Equality Index is a tool to measure the progress of gender equality in the EU, giving more visibility to areas that need improvement and ultimately supporting policy makers to design more effective gender equal...
Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/10...
Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024 Dijon, France, 08 mars 2024 – 07:30 CET - Crossject (ISIN : FR0011716265 ; Euronext : ALCJ), une société pharmaceutique spécialisée qui développe des auto-injecteurs sans aiguille dédiés aux situations d’urgence, annonce aujourd'hui que son score de l'index européen d’égalité femmes-hommes a atteint 96/100 pour 2024 et pour la troisième année consécutive est supérieur à 90 %. . L'index Egalité femmes-hommes est un outil permettant de mesurer les progrès réalisés au sein de l’Union européenne en matière d’égal...
- Fabrice Farigoule
Securing the financing needs
Securing the financing needs FINANCING ISSUE With the issuance of bonds, the details of which are given below, the group is securing its short-term financing. We will integrate this new financing in our model. Depending on a number of assumptions (partial or total conversion, interest paid, cash repayments, etc.) our target is price is likely to go down, even if the upside will remain significant in any case. FACT The group has announced an issue of 70 amortizable bonds convertible into new...
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
Crossject obtains a financing up to €12 million, in two tranches
Crossject obtains a financing up to €12 million, in two tranches Dijon, February 27, 2024 at 8:30am Crossject obtains a financing up to €12 million, in two tranches,from an entity managed by Heights Capital Management, in issued bondsconvertible in new shares, with a conversion premium of 35%1, or repayable (in cash and/or stocks, according to the company’s options) over 36 months at a rate of 7%2. CROSSJECT (ISIN: FR0011716265; Stock symbol: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations, , announces today the issue, waiving preferent...
Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tran...
Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tranches Dijon, le 27 février 2024 à 08h30 Crossject obtient un financement jusqu’à 12 millions d’euros en 2 tranches, auprès d’une entité gérée par Heights Capital Management, sous forme d’émission d’obligations convertibles en actions nouvelles, moyennant une prime de 35%1, ou remboursables (en numéraire et/ou actions, au choix de la société) sur 36 mois au taux de 7%2. CROSSJECT (ISIN : FR0011716265 ; Mnémonique : ALCJ), société pharmaceutique spécialisée dans le développement d’auto-injecteurs sans aiguille dédiés a...
- Fabrice Farigoule
No news is not always good news...
No news is not always good news... STRATEGIC PLAN The presentation held on Tuesday gave little information (if any) on the recent developments of the company. We regret that no further details were given with respect to the filing processes in the US (Emergency Use Authorization), in particular concerning the timing. We also regret that it will take a long time (end of April!) to have more flavour on the FY23 accounts and financial perspectives to cope with the extra financing needed. In short...
- Aurelien Sivignon
MERY MERCIALYS SA
TYRES NOKIAN RENKAAT OYJ
ABVX ABIVAX SA
WHA WERELDHAVE N.V.
LNA LNA SANTE SA
MBB MBB INDUSTRIES SE
BAMNB KONINKLIJKE BAM GROEP NV
VASTN VASTNED RETAIL NV
AALB AALBERTS N.V.
MELE MELEXIS NV
TKO TIKEHAU CAPITAL SCA
UNI UNICAJA BANCO S.A.
JEN JENOPTIK AG
TMV TEAMVIEWER AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
ECMPA EUROCOMMERCIAL PROPERTIES NV
- Aurelien Sivignon
MERY MERCIALYS SA
TYRES NOKIAN RENKAAT OYJ
ABVX ABIVAX SA
WHA WERELDHAVE N.V.
LNA LNA SANTE SA
MBB MBB INDUSTRIES SE
BAMNB KONINKLIJKE BAM GROEP NV
VASTN VASTNED RETAIL NV
AALB AALBERTS N.V.
MELE MELEXIS NV
TKO TIKEHAU CAPITAL SCA
UNI UNICAJA BANCO S.A.
JEN JENOPTIK AG
TMV TEAMVIEWER AG
COP COMPUGROUP MEDICAL SE & CO. KGAA
ECMPA EUROCOMMERCIAL PROPERTIES NV
- Martial Descoutures
- Oussema Denguir
Crossject : Strategic update: no transformative announcements at this ...
>Update on the 2024 road map - Crossject provided an update yesterday on the group’s latest developments and its road map for 2024. The key takeaways were as follows: 1 / Progress of the regulatory process in the US for Zepizure: no change at this stage to the previously announced timetable. Despite ongoing discussions with the FDA, management still expects an Emergency Use Authorisation (EUA) in the coming weeks (we are modelling first shipments in Q2 2024). 2/ Comme...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.